Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

30.39 +1.09 (+3.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug ↗
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way. 
Via Benzinga
News headline image
Analyst Ratings for Travere Therapeutics ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Latest Analyst Ratings for Travere Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Expert Ratings for Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Travere Therapeutics ↗
 
Via Benzinga
News headline image
11 Analysts Have This to Say About Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
Travere Therapeutics Reports Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks That Could Be Big-Time Winners ↗
These stocks come with significant risks. But they could generate huge returns over time. 
Via The Motley Fool
News headline image
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan ↗
Travere Therapeutics shares have lost nearly 30% since early May. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Report Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
News headline image
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks With Blockbuster Potential ↗
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.